Relevant bibliographies by topics / Pyrazolopyrimidines

Academic literature on the topic 'Pyrazolopyrimidines'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pyrazolopyrimidines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pyrazolopyrimidines"

1

George, CFP. "Pyrazolopyrimidines." Lancet 358, no. 9293 (November 2001): 1623–26. http://dx.doi.org/10.1016/s0140-6736(01)06656-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wald, Jiri, Marion Pasin, Martina Richter, Christin Walther, Neann Mathai, Johannes Kirchmair, Vadim A. Makarov, et al. "Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site." Proceedings of the National Academy of Sciences 116, no. 38 (August 28, 2019): 19109–15. http://dx.doi.org/10.1073/pnas.1904732116.

Full text
Abstract:
Viral inhibitors, such as pleconaril and vapendavir, target conserved regions in the capsids of rhinoviruses (RVs) and enteroviruses (EVs) by binding to a hydrophobic pocket in viral capsid protein 1 (VP1). In resistant RVs and EVs, bulky residues in this pocket prevent their binding. However, recently developed pyrazolopyrimidines inhibit pleconaril-resistant RVs and EVs, and computational modeling has suggested that they also bind to the hydrophobic pocket in VP1. We studied the mechanism of inhibition of pleconaril-resistant RVs using RV-B5 (1 of the 7 naturally pleconaril-resistant rhinoviruses) and OBR-5-340, a bioavailable pyrazolopyrimidine with proven in vivo activity, and determined the 3D-structure of the protein-ligand complex to 3.6 Å with cryoelectron microscopy. Our data indicate that, similar to other capsid binders, OBR-5-340 induces thermostability and inhibits viral adsorption and uncoating. However, we found that OBR-5-340 attaches closer to the entrance of the pocket than most other capsid binders, whose viral complexes have been studied so far, showing only marginal overlaps of the attachment sites. Comparing the experimentally determined 3D structure with the control, RV-B5 incubated with solvent only and determined to 3.2 Å, revealed no gross conformational changes upon OBR-5-340 binding. The pocket of the naturally OBR-5-340-resistant RV-A89 likewise incubated with OBR-5-340 and solved to 2.9 Å was empty. Pyrazolopyrimidines have a rigid molecular scaffold and may thus be less affected by a loss of entropy upon binding. They interact with less-conserved regions than known capsid binders. Overall, pyrazolopyrimidines could be more suitable for the development of new, broadly active inhibitors.
APA, Harvard, Vancouver, ISO, and other styles
3

Lu, Shi-Han, Po-Lin Liu, and Fung Fuh Wong. "Vilsmeier reagent-mediated synthesis of 6-[(formyloxy)methyl]-pyrazolopyrimidines via a one-pot multiple tandem reaction." RSC Advances 5, no. 58 (2015): 47098–107. http://dx.doi.org/10.1039/c5ra07707a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Agrebi, Asma, Fatma Allouche, Hamadi Fetoui, and Fakher Chabchoub. "Synthesis and biological evaluation of new pyrazolo[3,4-d]pyrimidine derivatives." Mediterranean Journal of Chemistry 3, no. 2 (May 13, 2014): 864. http://dx.doi.org/10.13171/mjc.3.2.2014.13.05.23agrebi.

Full text
Abstract:
<p class="Default">Several new pyrazolopyrimidine compounds were achieved from aminocyanopyarazole <strong>1</strong>. The starting material <strong>1 </strong>was initially coupled with orthoester at refluxed with various primary amines, ammonia, hydrazines and hydroxylamine to furnish a series of pyrazolo[3,4-<em>d</em>]pyrimidines. The reaction of imidate <strong>2a-b </strong>with hydrazide derivatives led to the formation of pyrazolo[3,4-<em>d</em>][1,2,4]triazolo[4,3-<em>c</em>]pyrimidines. Some of the synthesized compounds <strong>3a </strong>and <strong>4c </strong>were evaluated for their anti-inflammatory, antipyretic and nociceptive activities. We start by studing the toxicity of these two molecules by measuring the corresponding DL50. The DL50 of <strong>3a </strong>and <strong>4c </strong>are estimated to 1333.2mg / kg and 1593.5mg / kg respectively. Pharmacological evaluation showed that compounds <strong>3a </strong>and <strong>4c </strong>at doses (5.5-22.2 mg / Kg, i.p) exhibited anti-inflammatory activities compared to Ibuprofen (150 mg / Kg, i.p), used as a refer ence drug. Further, our study showed that the injection of derived pyrazolopyrimidines on hyperthermic animal leads to a decrease in temperature after 1 hours of treatment compared to paracetamol used as reference. In addition, the injection of derived pyrazolopyrimidines at different doses contains a potent nociceptive activity. This effect is dose-dependent compared to aspirin.</p>
APA, Harvard, Vancouver, ISO, and other styles
5

Elnagdi, Mohamed Hilmy, Ahmed Hafiz Husein Elghandour, Mohamed Kamal Ahmed Ibrahim, and Ibrahim Saad Abdel Hafiz. "Studies with Polyfunctionally Substituted Heterocycles: Synthesis of New Pyridines, Naphtho[1,2-b]pyrans, Pyrazolo[3,4-b]pyridines and Pyrazolo[l,5-a]pyrimidines." Zeitschrift für Naturforschung B 47, no. 4 (April 1, 1992): 572–78. http://dx.doi.org/10.1515/znb-1992-0419.

Full text
Abstract:
A variety of new polyfunctionally substituted pyridines, naphthopyrans and pyrazolopyrimidines were prepared via reacting ylidenemalononitriles with thiophenol, thionaphthol, naphthols and or aminopyrazoles.
APA, Harvard, Vancouver, ISO, and other styles
6

Kolosov, Maksim A., Dmitriy A. Beloborodov, Valeriy D. Orlov, and Victor V. Dotsenko. "Catalyst-free Biginelli-type synthesis of new functionalized 4,7-dihydropyrazolo[1,5-a]pyrimidines." New Journal of Chemistry 40, no. 9 (2016): 7573–79. http://dx.doi.org/10.1039/c6nj00336b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

El-Dean, Adel M. Kamal, and Maisa E. Abdel-Moneam. "Synthesis of Pyrimidines, Thienopyrimidines, and Pyrazolopyrimidines." Phosphorus, Sulfur, and Silicon and the Related Elements 177, no. 12 (December 1, 2002): 2745–51. http://dx.doi.org/10.1080/10426500214894.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weitensteiner, Sabine B., Johanna Liebl, Vladimir Krystof, Libor Havlíček, Tomáš Gucký, Miroslav Strnad, Robert Fürst, Angelika M. Vollmar, and Stefan Zahler. "Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors." PLoS ONE 8, no. 1 (January 15, 2013): e54607. http://dx.doi.org/10.1371/journal.pone.0054607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rice, Kenneth D., Moon H. Kim, Joerg Bussenius, Neel K. Anand, Charles M. Blazey, Owen J. Bowles, Lynne Canne-Bannen, et al. "Pyrazolopyrimidines as dual Akt/p70S6K inhibitors." Bioorganic & Medicinal Chemistry Letters 22, no. 8 (April 2012): 2693–97. http://dx.doi.org/10.1016/j.bmcl.2012.03.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ahmed, Sayed A., Ahmed M. Hussein, Walaa G. M. Hozayen, Ahmed H. H. El-Ghandour, and Abdou O. Abdelhamid. "Synthesis of some pyrazolopyrimidines as purine analogues." Journal of Heterocyclic Chemistry 44, no. 4 (July 2007): 803–10. http://dx.doi.org/10.1002/jhet.5570440408.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pyrazolopyrimidines"

1

Scammells, Peter J., and n/a. "Pyrazolo(3,4-d)Pyrimidines and adenosine receptors: a structure/activity study." Griffith University. Division of Science and Technology, 1990. http://www4.gu.edu.au:8080/adt-root/public/adt-QGU20050826.141630.

Full text
Abstract:
Pyrazolopyrimidines are a general class of compounds which exhibit Aj adenosine receptor affmity. A number of pyrazolo(3,4-d)pyrimidine analogues of isoguanosine and i-methylisoguanosine has been synthesised. All compounds were tested forAi adenosine receptor affinity using a (311) R-PIA competitive binding assay. The N-i and N-5 positions were substituted with a number of different ailcyl and aryi groups. 3-Chiorophenyl substitution of the N-i position and butyl substitution of the N-5 position greatly enhanced the overall adenosine receptor affinity. Substitution by a methyl group at the N-7 position fixed the C-4 position in the imino tautomeric form. This resulted in a marked reduction in activity. The substitution of the N-2 position with a phenyl group produced an analogue with a similar structure to i,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine (PACPX). A 2-phenyl substituent was favourable for interaction with the adenosine receptor. A number of pyrazolo(3,4-d)pyrirnidine analogues of 4,6-bis-a-carbamoylethylthio-i-phenylthiopyrazolo(3,4-d)pyrinhidine (DJB-KK) has also been synthesised and tested for Aj adenosine receptor affinity. 4,6-Bis-alkylthio-1-phenylpyrazolo(3,4-d)pyrimidines with a-carbamoylethyl and u-carbamoylpropyi groups were compared. The additional methyiene of the a-carbamoylpropyl group produced increased adenosine receptor affinity. 6-a-Carbamoylethylthio-4-mercapto-1-phenylpyrazolo(3,4-d)pyrimidine and 4-cc-carbamoylethylthio- i-phenylpyrazolo(3,4-dlpyrimidine were compared. Substitution of the C-6 position maintained activity, while substitution of the C-4 reduced activity.
APA, Harvard, Vancouver, ISO, and other styles
2

Scammells, Peter. "Pyrazolo(3,4-d)Pyrimidines and adenosine receptors: a structure/activity study." Thesis, Griffith University, 1990. http://hdl.handle.net/10072/365214.

Full text
Abstract:
Pyrazolopyrimidines are a general class of compounds which exhibit Aj adenosine receptor affmity. A number of pyrazolo(3,4-d)pyrimidine analogues of isoguanosine and i-methylisoguanosine has been synthesised. All compounds were tested forAi adenosine receptor affinity using a (311) R-PIA competitive binding assay. The N-i and N-5 positions were substituted with a number of different ailcyl and aryi groups. 3-Chiorophenyl substitution of the N-i position and butyl substitution of the N-5 position greatly enhanced the overall adenosine receptor affinity. Substitution by a methyl group at the N-7 position fixed the C-4 position in the imino tautomeric form. This resulted in a marked reduction in activity. The substitution of the N-2 position with a phenyl group produced an analogue with a similar structure to i,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine (PACPX). A 2-phenyl substituent was favourable for interaction with the adenosine receptor. A number of pyrazolo(3,4-d)pyrirnidine analogues of 4,6-bis-a-carbamoylethylthio-i-phenylthiopyrazolo(3,4-d)pyrinhidine (DJB-KK) has also been synthesised and tested for Aj adenosine receptor affinity. 4,6-Bis-alkylthio-1-phenylpyrazolo(3,4-d)pyrimidines with a-carbamoylethyl and u-carbamoylpropyi groups were compared. The additional methyiene of the a-carbamoylpropyl group produced increased adenosine receptor affinity. 6-a-Carbamoylethylthio-4-mercapto-1-phenylpyrazolo(3,4-d)pyrimidine and 4-cc-carbamoylethylthio- i-phenylpyrazolo(3,4-dlpyrimidine were compared. Substitution of the C-6 position maintained activity, while substitution of the C-4 reduced activity.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
Division of Science and Technology
Full Text
APA, Harvard, Vancouver, ISO, and other styles
3

Le, Corre Laurent. "Synthèse et évaluation biologique d’inhibiteurs de FGFR3 de structure pyrazolooxadiazole, pyrido- et pyrazolopyrimidine." Thesis, Paris 5, 2012. http://www.theses.fr/2012PA05P636.

Full text
Abstract:
FGFR3 est un récepteur cellulaire impliqué dans de nombreux processus biologiques chez l’homme. La dérégulation de l’activité tyrosine kinase de FGFR3 est à l’origine d’anomalies de croissance osseuse et de certains cancers (myélome multiple, vessie). Le blocage de ce récepteur par des inhibiteurs compétitifs de l’ATP constitue une approche thérapeutique intéressante. La première partie de la thèse a concerné la préparation d’analogues du PD173074, inhibiteur nanomolaire de FGFR3, issu de l’industrie. Basée sur un squelette pyrido[2,3-d]pyrimidine, une chimiothèque de triazoles a été obtenue via une réaction de cycloaddition 1,3-dipolaire catalysée au cuivre (I). Parmi les 27 analogues synthétisés, le meilleur inhibiteur restaure ex vivo la croissance osseuse de fémurs de souris naines. Dans une seconde partie, nous avons développé deux nouvelles séries d’inhibiteurs de type pyrazolooxadiazole et pyrazolo[4,3-d]pyrimidine, à partir d’un précurseur pyrazole commun. Des procédures micro-ondes rapides et efficaces ont été utilisées pour conduire aux composés cibles. L’étude des relations structure-activité, réalisée sur une soixantaine de composés, a été validée par modélisation moléculaire. Le composé le plus actif présente une CI50 submicromolaire
FGFR3 is a cellular receptor involved in many human biological processes. Deregulated tyrosine kinase activity of the FGFR3 is at the origin of abnormal bone growth and some cancers (multiple myeloma, bladder). Blocking this receptor by ATP competitive inhibitors may constitute an interestingtherapeutic approach. The first part of this thesis concerned the preparation of analogues of PD173074, a nanomolar inhibitor of FGFR3, stemming from the industry. Based on pyrido [2,3-d] pyrimidine skeleton, a library of triazoles was obtained via copper (I)-catalyzed 1,3-dipolar cycloaddition. Among the 27 analogues synthesized, the best inhibitor restores bone growth of dwarf mice femurs ex vivo. In a second part, we have developed two new series of inhibitors based on pyrazolooxadiazole and pyrazolo [4,3-d] pyrimidine skeletons, derived from a common pyrazole precursor. Rapid and efficient microwave procedures were used to yield the target compounds. The study of structure-activity relationships, performed on sixty compounds, was confirmed by molecular modeling. The most active compound has a submicromolar IC50 value
APA, Harvard, Vancouver, ISO, and other styles
4

Cardoso, Inês Sofia Soares Gomes Lains. "Design and synthesis of a novel pyrazolopyrimidine compound as a potential kinase inhibitor." Master's thesis, 2016. http://hdl.handle.net/10451/34606.

Full text
Abstract:
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2016
Cancer is a generic term for a group of diseases in which abnormal cells have a fast and uncontrolled growth and proliferation, invading neighbouring tissues and spreading to parts of the body different from where it started. Cancer is placed second at the most important causes of death and morbidity in Europe and accounts for 1 in every 7 deaths worldwide, which is more than HIV, tuberculosis and malaria combined. Furthermore, the number of new cases worldwide is expected to rise by about 70% over the next 20 years due to the growth and aging of the population. Nowadays, there are several options of treatment available for different types of cancer. However, current treatment modalities remain inadequate and in need of improvement regarding selectivity, potency and toxicity. For this reason, both academia and pharmaceutical industry have shown interest in deeply investigating carcinogenesis at a molecular level, improving existing drugs and discovering new compounds for cancer treatment. Given the role of proteins kinases and phosphorylation processes in carcinogenesis by driving many of the hallmark phenotypes of cancer biology, kinases are privileged targets of new antineoplasic therapies and pharmacological tools have been developed to inhibit protein phosphorylation. Recently, several kinase inhibitors have been studied and approved for the treatment of some types of cancer, such as Imatinib, Sorafenib, among others. Among kinases inhibitors, pyrazolopyrimidines-derived compounds have been investigated and are used as treatment for several diseases, acting like antineoplasic, antivirals, and tuberculostatic agents, among others. Different kinase inhibitors with pyrazolopyrimidines as central core structure were studied and produced. The aim of this thesis was to synthesize a pyrazolo[3,4-d]pyrimidine derivative chemically designed as a hybrid of two previously synthesized compounds containing the mentioned central core structure and which had good and complementary results on the IC50 test against subfamilies of kinases, suggesting an improvement in selectivity and efficacy. One part of each of the previously studied molecules were synthesized separately and attached to each other through a Suzuki-Miyaura cross-coupling reaction.
Cancro é um termo genérico que engloba um grupo de doenças nas quais células anormais crescem e proliferam rápida e descontroladamente, invadindo tecidos circundandes e outras partes do corpo distantes do local de origem. O cancro é a segunda causa de morte e morbilidade na Europa e é responsável por 1 em cada 7 mortes a nível mundial, representando mais do que HIV, tuberculose e malária no seu conjunto. Além disso, o número de novos casos, numa perspectiva mundial, é esperado que cresça em, aproximadamente, 70% nos próximos 20 anos, devido ao crescimento e envelhecimento da população. Actualmente, estão disponíveis várias opções de tratamento para diferentes tipos de cancro. No entanto, as modalidades actuais de tratamento permancem inadequadas e por melhorar, em relação à selectividade, potência e toxicidade. Por esta razão, a academia e a indústria farmacêutica têm demonstrado interesse em investigar a carcinogénese a um nível molecular, de forma a aperfeiçoar fármacos já existentes e a descobrir novos compostos para o tratamento do cancro. Considerando o papel das proteínas cinases e dos processos de fosforilação na carcinogénese, por conduzir muitos dos fenótipos característicos da biologia do cancro, as cinases representam um alvo priveligiado de novas terapias antineoplásicas e têm sido desenvolvidas ferramentais farmacológicas para inibir a fosforilação proteica. Recentemente, vários inibidores de cinases têm sido estudados e aprovados para o tratamento de alguns tipos de cancro, como por exemplo Imatinib, Sorafenib, entre outros. De entre os inibidores de cinases, os compostos derivados de pirazolo-pirimidinas têm sido investigados e são utilizados como tratamento para diversas doenças, actuando como antineoplásicos, antivirais e agentes tuberculoestáticos, entre outros. Foram estudados diferentes inibidores de cinases com o núcleo estrutural constituído por pirazolo-pirimidinas. O objectivo da presente tese consistiu na síntese de um derivado de pirazolo[3,4-d]pirimidina, quimicamente desenhado como um híbrido de dois compostos previamente sintetizados que contêm o mencionado núcleo estrutural e que apresentaram bons resultados, porém complementares, no teste de IC50 contra subfamílias de cinases, sugerindo a necessidade de melhoria quanto à selectividade e eficácia. Uma parte de cada uma das moléculas previamente estudadas foram sintetizadas separadamente e ligadas através de uma reacção de acoplamento de Suzuki-Miyaura.
APA, Harvard, Vancouver, ISO, and other styles
5

Chang, Hsin-Wen, and 張馨文. "A 3D-QSAR Study and Spatial Relation of Pyrazolopyrimidine Analogs and Their Target Protein mTOR." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/22976125865108904445.

Full text
Abstract:
碩士
國立高雄大學
生物科技研究所
99
mTOR (mammalian target of rapamycin), a key regulator of growth, metabolism, and proliferation, exists as two forms of protein complexes, mTORC1 (mammalian target of rapamycin complex 1) and mTORC2 (mammalian target of rapamycin complex 2). Since mTORC1 and mTORC2 are highly involved in mediation of PI3K (phosphoinositol 3-kinase) signaling pathways that are deregulated in human tumors, they have been recognized as cancer treatment targets. According to the inhibition domains, mTOR inhibitors are categorized into rapamycin-binding domain inhibitors and of kinase domain (ATP-binding domain) inhibitors. The former targets at mTORC1, whereas the latter, which has been more widely studied in recent years, targets at both mTORC1 and mTORC2. Because of close similarity between kinase domains of mTOR and PI3K, inhibitors toward mTOR inevitably show certain degree of inhibition on PI3K. Delicate design of mTOR inhibitors is expected to achieve a higher therapeutic index for enhanced clinical efficacy. Herein 3D-QSAR (three-dimensional quantitative structure-activity relationship) modeling is applied to investigate 83 pyrazolopyrimidine derivatives, which were published in 2009 and expected to serve as selective mTOR kinase domain inhibitors by Wyeth Research. Due to the lack of known mTOR structure, homology method is adopted to build mTOR in complex with one studied compound to provide details of possible binding mode and further to be correlated with the 3D-QSAR models. The constructed models suggest that R1 with a urea-modified benzene moiety enhances the hydrogen bonding interaction with mTOR Asp2195, whereas R2 carrying a piperidine in connection with a pyridine boosts the electrostatic interaction with mTOR His2247. On the other hand, the size of substituent on R1 and the connector between piperidine and pyridine on R2 play essential roles in PI3K/mTOR selectivity.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pyrazolopyrimidines"

1

Patrick, Graham. "Pyrazolopyrimidines." In Medicinal Chemistry, 241–44. Taylor & Francis, 2019. http://dx.doi.org/10.1201/9780429188572-54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Elnagdi, Mohamed Hilmy, Mohamed Rifaat Hamza Elmoghayar, and Galal Eldln Hamza Elgemeie. "Chemistry of Pyrazolopyrimidines." In Advances in Heterocyclic Chemistry Volume 41, 319–76. Elsevier, 1987. http://dx.doi.org/10.1016/s0065-2725(08)60164-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pyrazolopyrimidines"

1

Weiss, Andreas, Thomas Radimerski, Daniel Wyss, Rita Andraos, Alexandra Buhles, Dario Sterker, Jean Quancard, et al. "Abstract 1879: Pyrazolopyrimidines as novel selective allosteric MALT1 inhibitors with in vivo activity in ABC-DLBCL." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1879.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zask, Arie, Joshua Kaplan, Kevin Curran, Jeroen C. Verheijen, David J. Richard, Natasja Brooijmans, Eric Bennett, et al. "Abstract B145: Highly selective pyrazolopyrimidine mTOR inhibitors with profoundin vivoantitumor activity." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-b145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Negmeldin, Ahmed T., Mohammed K. AbdElhameid, Dalia Y. Alsaeedy, Fatiha Hammed, Rasha M. Allam, Walid El-Sayed, and Ahmed M. Al-Abd. "Abstract LB-236: Design, synthesis, and assessment of anticancer properties of pyrazolopyrimidine derivatives as Glycogen Synthase Kinase-3β inhibitors." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-lb-236.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pyrazolopyrimidines' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography